O Ortmann
Overview
Explore the profile of O Ortmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
1199
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ortmann O, Schuler-Toprak S, Kast K
J Cancer Res Clin Oncol
. 2024 Sep;
150(9):417.
PMID: 39259360
Purpose: To support doctors in counselling women with genetic predisposition for breast or gynecologic cancers on endocrine interventions. Methods: Evidence on the safety of endocrine interventions for fertility treatment, contraception,...
2.
Fernandez-Pacheco M, Ortmann O, Ignatov A, Inwald E
Arch Gynecol Obstet
. 2022 May;
307(4):1295-1309.
PMID: 35593951
Purpose: Cavity shaving (CS) is a surgical technique used in the treatment of breast cancer (BC). It may reduce margin positivity in histologic assessment and consequently reduces re- excision rates...
3.
Ortmann O, Blohmer J, Sibert N, Brucker S, Janni W, Wockel A, et al.
J Cancer Res Clin Oncol
. 2022 Apr;
149(3):1195-1209.
PMID: 35380257
Neoadjuvant chemotherapy (NACT) is frequently used in patients with early breast cancer. Randomized controlled trials have demonstrated similar survival after NACT or adjuvant chemotherapy (ACT). However, certain subtypes may benefit...
4.
Huber D, Seitz S, Kast K, Emons G, Ortmann O
Arch Gynecol Obstet
. 2021 Oct;
305(6):1627.
PMID: 34618215
No abstract available.
5.
Ortmann O, Torode J, Schmiegel W, Thomssen C, Hakama M, Basu P, et al.
J Cancer Res Clin Oncol
. 2021 Jul;
147(12):3773.
PMID: 34213663
No abstract available.
6.
Huber D, Seitz S, Kast K, Emons G, Ortmann O
J Cancer Res Clin Oncol
. 2021 Apr;
147(7):2035-2045.
PMID: 33885953
Purpose: BRCA mutation carriers have an increased risk of developing breast or ovarian cancer. Risk-reducing bilateral salpingo-oophorectomy (RRBSO) is associated with a decrease in risk for tubal and ovarian cancer....
7.
8.
Huber D, Seitz S, Kast K, Emons G, Ortmann O
Arch Gynecol Obstet
. 2020 Jul;
302(3):715-720.
PMID: 32719921
Purpose: Mutations in the genes BRCA1 and BRCA2 represent a significant risk factor for ovarian and breast cancer. With increasing number and success rates, fertility protection and treatment are gaining...
9.
Ortmann O, Torode J, Schmiegel W, Thomssen C, Hakama M, Basu P, et al.
J Cancer Res Clin Oncol
. 2020 Apr;
146(7):1813-1818.
PMID: 32270287
Purpose: To identify key factors for the best practice of knowledge transfer from high-income settings to low- and middle-income settings. Results: Interactive sessions led to the identification of European learnings...
10.
Huber D, Seitz S, Kast K, Emons G, Ortmann O
Arch Gynecol Obstet
. 2020 Mar;
301(4):875-884.
PMID: 32140806
Purpose: BRCA mutation carriers have an increased risk of developing breast or ovarian cancer. Oral contraception (OC) is known to increase breast cancer and reduce ovarian cancer risk in the...